Akero Therapeutics, Inc.
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
AKRO | NDAQ
Overview
Corporate Details
- ISIN(s):
- US00973Y1082
- LEI:
- Country:
- United States of America
- Address:
- 601 GATEWAY BOULEVARD, SUITE 350, 94080 SOUTH SAN FRANCISCO
- Website:
- https://akerotx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Akero Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing transformative therapies for patients with serious metabolic diseases. The company's primary focus is on conditions with high unmet medical need. Its lead product candidate, Efruxifermin (EFX), is an investigational drug being evaluated in multiple clinical trials as a differentiated, potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Akero Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Akero Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Akero Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
